OPERA: Responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy

Raffaele Bruno, Giuseppe Cariti, Paola Nasta, Amedeo Capetti, Veronica Ravasio, Massimo Galli, Enzo Raise, Giulio Palmieri, Claudio Iannacone, Massimo Puoti

Research output: Contribution to journalArticle

Abstract

Background & Aims: Hepatitis C virus (HCV) genotype 3 (G3) is common among HIV/HCV co-infected individuals and associated with moderate sustained virological response (SVR) rates with pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy, while G2 is less frequent and associated with higher SVR. To determine SVR and other response rates, identify SVR predictors and analyse differences between G2 and G3 with PEG-IFN/RBV in a large HIV/HCV G2/3 patient population. Methods: This subgroup analysis of the prospective, observational OPERA (Optimized Pegylated interferon Efficacy and anti-Retroviral Approach) study was conducted between 2005 and 2011 in Italy in PEG-IFN/RBV-naïve HIV/HCV patients. The primary efficacy endpoint was SVR rate (HCV RNA

Original languageEnglish
Pages (from-to)120-129
Number of pages10
JournalLiver International
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Keywords

  • Hepatitis C
  • HIV infections
  • Peginterferon alfa-2a
  • Ribavirin

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'OPERA: Responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy'. Together they form a unique fingerprint.

  • Cite this

    Bruno, R., Cariti, G., Nasta, P., Capetti, A., Ravasio, V., Galli, M., Raise, E., Palmieri, G., Iannacone, C., & Puoti, M. (2015). OPERA: Responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy. Liver International, 35(1), 120-129. https://doi.org/10.1111/liv.12641